Cancer Research Technology (CRT) is the technology transfer arm of Cancer Research UK. CRT identifies and protects new cancer discoveries and inventions arising from publicly funded cancer research. The marketed products developed by CRT includes Temodal®/Temodar® (temozolomide) for treating glioma, Tomudex® (raltitrexed) for treating colorectal cancer and Zinecard® (dexrazoxane) useful as cardioprotectant in combination with doxorubicin. CRT also has developed satraplatin which is in phase 3 clinical trials for treating prostate cancer.